PDF
ePub
Citation
Print
Abstract
Cardiovascular disease (CVD) is the major cause of mortality in type 2 diabetes mellitus. CVD is a clinical manifestation of atherosclerosis, a chronic and progressive inflammatory disease characterized by a long asymptomatic phase. Progression of atherosclerosis can lead to the occurrence of acute cardiovascular events. Atherosclerosis can be identified during the subclinical phase by several methods, including using biomarkers, pulse wave velocity, augmentation index, flow-mediated dilation, carotid ultrasound, and calcium score. The appropriate criteria for identifying asymptomatic patients with type 2 diabetes who should undergo CVD screening and therapeutic intervention remain controversial. Non-invasive methods, such as markers of subclinical atherosclerosis, may aid in risk stratification and the design of tailored therapies for patients with type 2 diabetes mellitus.
References
1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002. 287:2570–2581.
2. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003. 108:1527–1532.
3. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 44:Suppl 2. S14–S21.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998. 339:229–234.
5. Lockhart CJ, Hamilton PK, McVeigh KA, McVeigh GE. A cardiologist view of vascular disease in diabetes. Diabetes Obes Metab. 2008. 10:279–292.
6. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998. 97:1837–1847.
7. Barzi F, Patel A, Gu D, Sritara P, Lam TH, Rodgers A, Woodward M. Asia Pacific Cohort Studies Collaboration. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health. 2007. 61:115–121.
8. Stevens RJ, Kothari V, Adler AI, Stratton IM. United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001. 101:671–679.
9. Calabró P, Willerson JT, Yeh ETH. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003. 108:1930–1932.
10. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001. 158:1039–1051.
11. Venugopal SK, Devaraj S, Jialal . Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol. 2005. 166:1265–1271.
12. Calabró P, Chang DW, Willerson JT, Yeh ETH. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation (research correspondence). J Am Coll Cardiol. 2005. 46:1112–1113.
13. Khreiss T, József L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation. 2004. 109:2016–2022.
14. Lagrand WK, Niessen HWM, Wolbink G-J, Jaspars LH, Visser CA, Verheugt WA, Meijer CJLM, Hack E. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation. 1997. 95:97–103.
15. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A. Targeting C-reactive protein for the treatment of cardiovascular disease (letter). Nature. 2006. 440:1217–1221.
16. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F. Centers for Disease Control and Prevention: American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003. 107:499–511.
17. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ. for the SHAPE Task Force. From vulnerable plaque to vulnerable patient-part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006. 98:2H–15H.
18. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002. 252:283–294.
19. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001. 286:327–334.
20. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities(ARIC) study. Am J Epidemiol. 2000. 151:478–487.
21. Touboul PJ, Elbaz A, Koller C. Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Genetique de l'Infarctus Cerebral(GENIC) case-control study: the GENIC Investigators. Circulation. 2000. 102:313–318.
22. Bots ML, Hoes AW, Koudstaal PJ. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997. 96:1432–1437.
23. Roman MJ, Naqvi TZ, Gardin JM, Gerhard-Herman M, Jaff M, Mohler E. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr. 2006. 19:943–954.
24. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS. American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. Am Soc Echocardiogr. 2008. 2:93–111.
25. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N. Mannheim Carotid Intima-media Thickness Consensus(2004-2006): an update on behalf of the advisory board of the 3rd and 4th watching the risk symposium 13th and 15th European stroke conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007. 23:75–80.
26. Bae JH, Seung KB, Jung HO, Kim KY, Yoo KD, Kim CM, Cho Sw, Cho SK, Kim YK, Rhee MY, Cho MC, Kim KS, Jin SW, Lee JM, Kim KS, Hyun DW, Cho Yk, Seong IW, Jeong JO, Park SC, Jeong JY, Woo JT, Koh GK, Lim SW. Analysis of Korean Carotid Intima-Media Thickness in Korean Healthy Subjects and Patients with Risk Factors: Korea Multi-Center Epidemiological Study. Korean Circulation J. 2005. 35:513–524.
27. Kim HJ, Won YJ, Kim DJ, Ahn CW, Cha BS, Lim SK, Kim KR, Lee HC, Huh KB. Normative Data of Intima-medial Thickness in Korean Adults and the Estimation of the Relative Risk of Macrovascular Diseases Using this Data in Type 2 Diabetic Subjects. J Korean Diabetes Assoc. 2003. 27:288–297.
28. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997. 146:483–494.
29. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study. N Engl J Med. 1999. 340:14–22.
30. Brohall G, Odén A, Fagerberg B. Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med. 2006. 23:609–616.
31. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987. 316:1371–1375.
32. Miura H, Wachtel RE, Liu Y, Loberiza FR Jr, Saito T, Miura M, Gutterman DD. Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-activated K(+) channels. Circulation. 2001. 103:1992–1998.
33. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Lüscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995. 91:1314–1319.
34. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002. 39:257–265.
35. Schroeder S, Enderle MD, Ossen R, Meisner C, Baumbach A, Pfohl M, Herdeg C, Oberhoff M, Haering HU, Karsch KR. Noninvasive determination of endothelium-mediated vasodilation as a screening screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. Am Heart J. 1999. 138:731–739.
36. Ceriello A, Esposito K, Piconi L, Ihnat M, Thorpe J, Testa R, Bonfigli AR, Giugliano D. Glucose "peak" and glucose "spike": Impact on endothelial function and oxidative stress. Diabetes Res Clin Pract. 2008. 82:262–267.
37. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, Lima JA, Crouse JR, Herrington DM. Predictive Value of Brachial Flow-Mediated Dilation for Incident Cardiovascular Events in a Population-Based Study. The Multi-Ethnic Study of Atherosclerosis. Circulation. 2009. 07. 27. [Epub ahead of print].
38. Nitenberg A, Pham I, Antony I, Valensi P, Attali JR, Chemla D. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study. Atherosclerosis. 2005. 183:113–120.
39. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a 'set up' for vascular disease. Circulation. 2003. 107:139–146.
40. Simons PC, Algra A, Bots ML, Grobbee DE, van der Graaf Y. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation. 1999. 100:951–957.
41. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness: definitions and reference values. Am J Hypertens. 2002. 15:426–444.
42. Park HY, Lee SY, Cho SW, Kwon SU, Namgung J, Hyung J, Lee WR. Correlations between the left ventricular diastolic function and aortic stiffness in healthy aged subjects. Korean Circ J. 2006. 36:393–399.
43. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, Schwartz RS. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying metholdology. J Am Coll Cardiol. 1998. 31:126–133.
44. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990. 15:827–832.
45. Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004. 43:1663–1669.
46. Khaleeli E, Peters SR, Bobrowsky K, Oudiz RJ, Ko JY, Budoff MJ. Diabetes and the associated incidence of subclinical atherosclerosis and coronary artery disease: implications for management. Am Heart J. 2001. 141:637–644.
47. Hoff JA, Quinn L, Sevrukov A, Lipton RB, Daviglus M, Garside DB, Ajmere NK, Gandhi S, Kondos GT. The prevalence of coronary artery calcium among diabetic individuals without known coronary artery disease. J Am Coll Cardiol. 2003. 41:1008–1012.
48. Schurgin S, Rich S, Mazzone T. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care. 2001. 24:335–338.
49. Reaven PD, Sacks J. Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes. Diabetologia. 2005. 48:379–385.
50. Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004. 43:1663–1669.
51. Anand DV, Lim E, Hopkins D, Corder R, Shaw LJ, Sharp P, Lipkin D, Lahiri A. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J. 2006. 27:713–721.
52. Qu W, Le TT, Azen SP, Xiang M, Wong ND, Doherty TM, Detrano RC. Value of coronary artery calcium scanning by computed tomography for predicting coronary heart disease in diabetic subjects. Diabetes Care. 2003. 26:905–910.
53. Dennie CJ, Jeipsic J, Brydie A. Canadian Association of Radiologists: Consensus guidelines and Standards for Cardiac CT. Can Assoc Radiol J. 2009. 60:19–34.
54. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003. 348:383–393.
XML Download